Ⅲ期肝癌切除术前介入治疗的临床价值

Clinical values of interventional therapeutics prior to HCC resection at stage Ⅲ

目的探讨Ⅲ期(TNM分期法)肝细胞性肝癌(HCC)切除术前介入治疗对预防术后复发及提高患者生存率的临床价值。方法回顾分析2000年1月至2005年1月40例Ⅲ期HCC患者临床资料,其中20例术前辅以介入治疗(介入组),另外20例作为同期对照组(未介入组),比较两组的累计生存率和无瘤生存率。结果介入组和未介入组1、2年无瘤生存率比较差异有统计学意义(P<0.05);介入组1、2年生存率(80%、60%)亦高于未介入组(55%、35%),两组术后累计生存率比较差异有统计学意义(P<0.05)。介入组患者均未出现与介入治疗相关的肝、肾毒性或影响手术的不良反应。结论Ⅲ期肝癌(HCC)术前辅以介入治疗治疗可显著提高手术后生存率,减少复发。

Aim To probe into what clinical value the interventional therapeutics produces in preventing the postoperative recrudescence and increasing patients＇ survival rate prior to HCC resection at stage Ⅲ. Methods The clinical data of 40 patients suffering HCC at stage Ⅲ ranging from January 2000 to January 2005 were analyzed, twenty of whom received interventional therapeutics and another twenty acted as a concurrent control group and then the author contrasted the two groups accumulative survival rate and non-lump survival one. Results The difference in non-lump survival rate （ P 〈 0.05 ） is statistically significant whithin one year and two years respectively. The intercurrent group patients＇survival rate is 80% and 60% while the non-intercurrent one is 55% and 35% whithin one year and two years respectively,and therefore the two groups postoperative accumulative survival rate（ P 〈 0.05 ） is statisitcally meaningful. The intercurrent sufferers never encounter intercurrent therapeutical side effects related to liver and kidney toxicity and surgery interference. Conclusion Implementing interventional therapeutics in HCC resection at stage Ⅲ can remarkably improve the patients＇ postoperative survival rate and abate recrudescence.